TP53 and ovarian serous carcinoma: Lastly, wee1 inhibitors active in synthetic lethality in p53 mutant high-grade serous ovarian carcinoma are being translated to other p53 mutant gynecologic tumors, such as endometrial serous carcinoma [14].